Department of Nephrology of the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Department of Nephrology of the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Biochem Biophys Res Commun. 2014 Jul 25;450(2):1051-7. doi: 10.1016/j.bbrc.2014.06.107. Epub 2014 Jun 27.
Hyperlipidemia is an independent risk factor for renal disease, and lipid deposition is associated with glomerulosclerosis. The angiotensin converting enzyme 2-angiotensin-(1-7)-Mas axis (ACE2-Ang-(1-7)-Mas axis) has been reported to participate in lipid metabolic regulation but its mechanism remains unclear. We hypothesized Ang-(1-7) would reduce lipid uptake in human mesangial cells (HMCs) by regulating the low density lipoprotein receptor-sterol regulatory element binding proteins 2-SREBP cleavage activating protein (LDLr-SREBP2-SCAP) negative feedback system, and improve glomerulosclerosis by regulating the transforming growth factor-β1 (TGF-β1). In this study we found that ACE2 was undetected in HMCs. The administration of LDL caused normal LDLr-SREBPs-SCAP negative feedback effect. Exogenous Ang-(1-7) enhanced this negative feedback effect via down-regulating LDLr, SREBP2, and SCAP expression, and effectively inhibited LDL-induced lipid deposition and cholesterol increases. This enhanced inhibitory effect was reversed by the Mas receptor antagonist A-779. Meanwhile, Ang-(1-7) significantly decreased the high LDL-induced production of TGF-β1, an effect blocked by A-779. Interestingly, HMCs treated with Ang-(1-7) alone activated the TGF-β1 expression. Our results suggested that Ang-(1-7) inhibits LDL accumulation and decreases cholesterol levels via modulating the LDLr-SREBPs-SCAP negative feedback system through the Mas receptor. Moreover, Ang-(1-7) exhibits a dual regulatory effect on TGF-β1 in HMCs.
高脂血症是肾病的独立危险因素,脂质沉积与肾小球硬化有关。血管紧张素转换酶 2-血管紧张素-(1-7)-Mas 轴 (ACE2-Ang-(1-7)-Mas 轴) 已被报道参与脂质代谢调节,但具体机制尚不清楚。我们假设 Ang-(1-7) 通过调节低密度脂蛋白受体-固醇调节元件结合蛋白 2-SREBP 切割激活蛋白 (LDLr-SREBP2-SCAP) 负反馈系统,减少人肾小球系膜细胞 (HMC) 中的脂质摄取,并通过调节转化生长因子-β1 (TGF-β1) 改善肾小球硬化。在这项研究中,我们发现 HMC 中未检测到 ACE2。LDL 的给药导致正常的 LDLr-SREBPs-SCAP 负反馈效应。外源性 Ang-(1-7) 通过下调 LDLr、SREBP2 和 SCAP 的表达增强了这种负反馈效应,并有效抑制了 LDL 诱导的脂质沉积和胆固醇增加。Mas 受体拮抗剂 A-779 逆转了这种增强的抑制作用。同时,Ang-(1-7) 显著降低了高 LDL 诱导的 TGF-β1 产生,A-779 阻断了这种作用。有趣的是,单独用 Ang-(1-7) 处理的 HMC 激活了 TGF-β1 的表达。我们的结果表明,Ang-(1-7) 通过 Mas 受体调节 LDLr-SREBPs-SCAP 负反馈系统抑制 LDL 积累并降低胆固醇水平。此外,Ang-(1-7) 在 HMC 中对 TGF-β1 表现出双重调节作用。